CAR NK-92 cells targeting DLL3 kill effectively small cell lung cancer cells in vitro and in vivo.
Sign Up to like & getrecommendations! Published in 2022 at "Journal of leukocyte biology"
DOI: 10.1002/jlb.5ma0122-467r
Abstract: Small cell lung cancer (SCLC) is characterized by a high relapse rate, drug tolerance, and limited treatment choices. Chimeric antigen receptor (CAR)-modified NK cells represent a promising immunotherapeutic modality for cancer treatment. However, their potential… read more here.
Keywords: dll3; dll3 car; car cells; cancer ... See more keywords
Expression of delta-like protein 3 is reproducibly present in a subset of small cell lung carcinomas and pulmonary carcinoid tumors.
Sign Up to like & getrecommendations! Published in 2019 at "Lung cancer"
DOI: 10.1016/j.lungcan.2019.07.016
Abstract: OBJECTIVES Delta-like protein 3 (DLL3), an inhibitory Notch ligand, is the target for rovalpituzumab tesirine in development for the treatment of small cell lung cancer (SCLC). We studied the expression of DLL3, its reproducibility and… read more here.
Keywords: dll3; expression; lung; carcinoid tumors ... See more keywords
Lfng and Dll3 cooperate to modulate protein interactions in cis and coordinate oscillatory Notch pathway activation in the segmentation clock.
Sign Up to like & getrecommendations! Published in 2022 at "Developmental biology"
DOI: 10.1016/j.ydbio.2022.04.004
Abstract: In mammalian development, oscillatory activation of Notch signaling is required for segmentation clock function during somitogenesis. Notch activity oscillations are synchronized between neighboring cells in the presomitic mesoderm (PSM) and have a period that matches… read more here.
Keywords: dll3; activation; notch; activity ... See more keywords
Molecular modelling studies and identification of novel phytochemical inhibitor of DLL3
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Biomolecular Structure and Dynamics"
DOI: 10.1080/07391102.2022.2045224
Abstract: Abstract Prostate cancer has been recently considered the most diagnosed cancer in male. DLL3 is overexpressed in CRPC-NE but not in localised prostate cancer or BPH. There are no effective treatments for neuroendocrine differentiated prostate… read more here.
Keywords: prostate cancer; structure; molecular modelling; dll3 ... See more keywords
Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer
Sign Up to like & getrecommendations! Published in 2019 at "Science Translational Medicine"
DOI: 10.1126/scitranslmed.aav0891
Abstract: DLL3 is overexpressed in neuroendocrine prostate cancer and is a potential therapeutic target. Lessons from one tumor help with another Neuroendocrine prostate cancer is an aggressive tumor subtype that can arise late in the course… read more here.
Keywords: prostate; prostate cancer; neuroendocrine prostate; expression ... See more keywords
Abstract 3632: BiTE® antibody constructs for the treatment of SCLC
Sign Up to like & getrecommendations! Published in 2017 at "Cancer Research"
DOI: 10.1158/1538-7445.am2017-3632
Abstract: Small cell lung cancer (SCLC) is a highly aggressive neuroendocrine tumor with a poor prognosis and limited therapeutic options. Most patients present with extensive stage disease, where recent advances in immunotherapies, including bi-specific T cell… read more here.
Keywords: bite antibody; sclc; antibody; antibody constructs ... See more keywords
Abstract 1872: A DLL3/CD3/CD137 trispecific T cell engager shows potent antitumor activity in small cell lung cancer models
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-1872
Abstract: Background: Despite the approval of immune checkpoint inhibitors (ICIs), prognosis of small cell lung cancer (SCLC) remains poor. DLL3 is upregulated in SCLC whereas expression in normal tissues is minimal, representing the favorable profile as… read more here.
Keywords: cd3 cd137; dll3; cell; dll3 trispecific ... See more keywords
Differential expression of the Notch1 receptor, and its ligands Dll1, Dll3 and Dll4 in distinct human pituitary adenoma subtypes.
Sign Up to like & getrecommendations! Published in 2017 at "Oncology letters"
DOI: 10.3892/ol.2017.5997
Abstract: Pituitary adenoma (PA) is a common type of benign tumor of the pituitary gland that is characterized by specific signs and symptoms, primarily associated with hypersecretion of pituitary glycoprotein hormones (thyroid-stimulating, growth and adrenocorticotrophic hormones,… read more here.
Keywords: notch1 receptor; expression notch1; receptor; dll3 ... See more keywords
Prognostic value of delta-like protein 3 combined with thyroid transcription factor-1 in small-cell lung cancer
Sign Up to like & getrecommendations! Published in 2019 at "Oncology Letters"
DOI: 10.3892/ol.2019.10538
Abstract: Rovalpituzumab tesirine is a promising delta-like protein 3 (DLL3)-targeted antibody-drug conjugate for the treatment of small-cell lung cancer (SCLC). Thyroid transcription factor-1 (TTF-1) and DLL3 protein are associated with SCLC, and may be used to… read more here.
Keywords: protein; ttf; sclc; value ... See more keywords